Evotec SE announced that its biologics segment expanded a strategic partnership with Sandoz to provide biosimilars to the pharma company. Under the agreement, Evotec Biologics will receive appropriate remuneration following early scientific validation. Further funding will be tied to achieving development milestones from 2025. The expanded partnership solidifies the company’s commitment to providing a long-term…

Novartis announced today that it intends to separate Sandoz into a new, publicly traded standalone company through a 100% spinoff. The spinoff of the generics and biosimilars division of Novartis aims to maximize shareholder value by creating the top European generics company and a global leader in biosimilars, according to a news release. Such a…

On the heels of announcing a restructuring plan that would do away with approximately 8,000 positions, Novartis AG (NYSE:NVS) is reportedly considering spinning off its Sandoz generics arm. The company is likely to make a final decision by the end of the year, according to Bloomberg. Given the sluggish state of the economy, Novartis is likely…

Sandoz, a Novartis division, announced today that it extended and expanded a strategic collaboration agreement with Ares Genetics. Basel, Switzerland-baed Sandoz’s collaboration with Ares, aimed at driving innovation to develop solutions in the fight against antimicrobial resistance (AMR), was extended through January 31, 2025. According to a news release, the companies agreed to an extension…